Directorate Change

AstraZeneca PLC 06 June 2007 AstraZeneca CFO to join Goldman Sachs AstraZeneca PLC announces the resignation of its Chief Financial Officer, Jon Symonds, with effect from the end of July. Jon Symonds joined Zeneca in 1997 as CFO after 17 years at KPMG. Within months of joining, he was involved in the merger negotiations with Swedish pharmaceutical company, Astra. After completion of the merger in 1998, Jon was appointed as CFO for AstraZeneca PLC. 'Jon has played a critical role in driving AstraZeneca to become one of the leading, most focused and most successful pharmaceutical companies in the world. On a personal level, I have worked closely with him for several years and have valued his knowledge of the business, strategic thinking, and wise financial counsel enormously,' said David Brennan, CEO. Jon leaves AstraZeneca to join global investment banking, securities and investment management firm, Goldman Sachs in mid September as a managing director. His legacy at AstraZeneca includes a record of consistent strong financial performance and a mature, well structured global Finance leadership team. Louis Schweitzer, Chairman, commented, 'I have the utmost respect for Jon's personal and professional capabilities, he carries significant credit both for the success of the merger itself and for AstraZeneca's sound financial performance since 1998. I regret Jon's decision to leave AstraZeneca, however, the move to Goldman Sachs represents an exciting career challenge for him and I wish him every success with it.' An external search is underway to identify a successor. -Ends- June 6th 2007 Media Enquiries: Edel McCaffrey, Tel: +44 (0) 207 304 5034 Steve Brown, Tel: +44 (0) 207 304 5033 Investor Relations: Mina Blair, Tel: +44 (0) 207 304 5084 Jonathan Hunt, Tel: +44 (0) 207 304 5087 Karl Hard, Tel: +44 (0) 207 304 5322 Jorgen Winroth, Tel: +1 (212) 579 0506 Ed Seage, Tel: +1 302 886 4065 Goldman Sachs: Paul Kafka, Tel: +44(0) 207 774 4667 This information is provided by RNS The company news service from the London Stock Exchange

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings